CVS Group (LSE:CVSG), the FTSE 250 veterinary services provider, has spent the weeks since its 24 September full-year results buying back shares while setting out an outlook for growth after a period shaped by the Competition and Markets Authority (CMA) investigation into the veterinary …
Oxford Biomedica (LSE:OXB), the viral vector contract development and manufacturing organisation known as OXB, has spent the weeks since its 22 September interim results setting out how it plans to turn a fast-growing order book into profit. The half-year statement covering the six months …
Oxford Nanopore Technologies (LSE:ONT), the Oxford-based developer of DNA and RNA sequencing platforms, has spent much of 2026 trying to rebuild investor confidence after a bumpy period for its shares. Its interim results for the six months to 30 June, published on 19 August, …
Hikma Pharmaceuticals Plc (LSE:HIK), the London-listed generic and specialty drugmaker, has kept investors focused on execution in 2026, with management emphasising steady delivery across its injectables, branded and generics operations. Its interim results, published on 6 August 2026, showed modest top-line growth, firmer profitability …
Genus plc (LSE:GNS), the animal genetics specialist behind the PIC pig breeding and ABS bovine businesses, has given investors plenty to consider in recent weeks. Its preliminary results for the year ended 30 June 2026, released on 10 September, showed sharply higher profits, a …
Halma is in focus as investors reassess quality-growth and defensive businesses amid a sharp global wobble in artificial-intelligence-linked shares. Halma underperformed during recent sessions, with its shares falling around 5% on 15 October in a weak patch for selected premium-valued growth stocks. That makes …
• Smith & Nephew is followed as a medical-technology company whose results depend on procedure volumes, surgeon adoption, product launches and operational execution. Demand for orthopaedic and sports-medicine products can be influenced by hospital capacity, elective-surgery backlogs and healthcare budgets. Investors are also interested …
Shares in Fusion Antibodies (LSE:FAB) fell sharply on 15 October 2026 after the company published its AGM statement, including an H1 trading and R&D update, at 07:00 ahead of its annual general meeting. The update showed that unaudited revenue for the first half of …
Shares in Cizzle Biotechnology Holdings (LSE:CIZ) fell sharply on 15 October 2026 after the company released an announcement titled "Update on Launch of Lung Cancer Test in USA" at 07:00. The announcement, flagged as containing inside information, said that its North American licensee, Cizzle …
The renewed interest in Provexis (LSE:PXS) appears to stem from the sales guidance in its final results for the year to 31 March 2026, published on 30 September 2026. In that announcement, the company said it expects to report sales for the six months …